Oryzon Genomics (XMAD:ORY) COGS-to-Revenue : 0.00 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Oryzon Genomics COGS-to-Revenue?

Oryzon Genomics's Cost of Goods Sold for the three months ended in Sep. 2024 was €0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was €0.00 Mil.

Oryzon Genomics's COGS to Revenue for the three months ended in Sep. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Oryzon Genomics's Gross Margin % for the three months ended in Sep. 2024 was N/A%.

Oryzon Genomics COGS-to-Revenue Historical Data

The historical data trend for Oryzon Genomics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics COGS-to-Revenue Chart

Oryzon Genomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Oryzon Genomics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Oryzon Genomics COGS-to-Revenue Calculation

Oryzon Genomics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	-13.948	/	0
	=

Oryzon Genomics's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Oryzon Genomics (XMAD:ORY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Oryzon Genomics's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Oryzon Genomics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oryzon Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (XMAD:ORY) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ORYZF:USA 0RDB:UK ORN:Germany

Address

Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940

Website

http://www.oryzon.com

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics Headlines

No Headlines